INFI : Insider Transactions for Infinity Pharmaceuticals Inc

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

New Search

Get Insiders for :

Infinity Pharmaceuticals Inc (INFI)

$0.00 0.00 (0.00%) as of 4:30 Fri 4/19

Download

Exchange:

Nasdaq National Market

Security Type:

Common

Shares Out:

64,210,000

Market Cap:

N/A

Last Volume:

141

Avg Vol:

1,513,129

52 Week Range:

$0.000001 - $0.238

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Biotechnology

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	0	0	410,196	425,190
Total Sell Value	$0	$0	$28,714	$38,646
Total People Sold	0	0	1	2
Total Sell Transactions	0	0	1	2
End Date	2024-01-28	2023-10-27	2023-04-28	2022-04-28

Adjust Filter Settings

Records found: 227

Page 5 of 10

Filer's Name

Relation Title

Off-Dir-10%

Tran. Date

Form

Action

Price

Mkt Value

D/I

Shares

Holdings

Rank

3m +/-

Form

Palombella Vito J.

Chief Scientific Officer

• – –

2014-02-25

$15.00

$71,040

D/D

(4,736)

Palombella Vito J.

Chief Scientific Officer

• – –

2014-02-25

$2.04

$9,661

D/D

4,736

Roth David

Chief Medical OfficerOfficer

• – –

2014-01-31

$0.00

I/I

Palombella Vito J.

Chief Scientific Officer

• – –

2014-01-02

$13.52

$10,181

D/D

(753)

Palombella Vito J.

Chief Scientific Officer

• – –

2013-12-31

$11.74

$8,840

D/D

753

Evnin Anthony B

Director

– • –

2013-12-02

$14.56

$258,527

I/I

(17,756)

112,451

Evnin Anthony B

Director

– • –

2013-11-27

$14.56

$17,472

I/I

(1,200)

130,207

Evnin Anthony B

Director

– • –

2013-11-26

$14.72

$2,045,506

I/I

(138,961)

131,407

Evnin Anthony B

Director

– • –

2013-11-25

$15.40

$365,026

I/I

(23,703)

270,368

Palombella Vito J.

Chief Scientific Officer

• – –

2013-09-27

$17.28

$81,837

D/D

(4,736)

Palombella Vito J.

Chief Scientific Officer

• – –

2013-09-27

$2.04

$9,661

D/D

4,736

Perkins Adelene Q

Pres & Chief Executive Officer

• • –

2013-09-13

$20.50

$268,096

D/D

(13,076)

447,535

Perkins Adelene Q

Pres & Chief Executive Officer

• • –

2013-09-12

$20.81

$664,390

D/D

(31,924)

460,611

Palombella Vito J.

Chief Scientific Officer

• – –

2013-06-20

$18.53

$429,067

D/D

(23,150)

Palombella Vito J.

Chief Scientific Officer

• – –

2013-06-20

$1.72

$38,017

D/D

22,103

23,150

Beacon Co

10% Owner

– – •

2013-04-16

$38.40

$219,198,029

D/D

(5,708,282)

Rosebay Medical Co L.p.

10% Owner

– – •

2013-04-16

$38.40

$219,198,067

D/D

(5,708,283)

Venuti Michael C

Director

– • –

2013-03-06

$16.80

$105,000

D/D

6,250

56,250

Selby Norman C

Director

– • –

2012-12-14

$8.87

$22,175

D/D

2,500

7,500

Perkins Adelene Q

Pres & Chief Executive Officer

• • –

2012-12-07

$3.48

$1,279,198

D/D

175,997

492,535

Evnin Anthony B

Director

– • –

2012-11-29

$24.62

$118,958

I/I

(4,832)

294,071

Evnin Anthony B

Director

– • –

2012-11-27

$25.28

$446,171

I/I

(17,648)

298,903

Evnin Anthony B

Director

– • –

2012-11-27

$5.63

$407,724

D/D

58,657

59,580

Evnin Anthony B

Director

– • –

2012-11-26

4/A

$0.00

D/D

8,743

67,400

Evnin Anthony B

Director

– • –

2012-11-26

$0.00

D/D

923

227 Records found	1 2 3 4 5 6 7 8 9 Next	Page 5 of 10

Transaction Code Key:				Ownership Code Key
B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
OE	- Options Exercised	A	- Acquired
IO	- Initital Ownership	D	- Disposed

Summary:

Chart:

3m +/-: